Merck Approves First Oral Pill for High Cholesterol

The approval of Merck's first oral pill for high cholesterol is a positive development, expanding the company's product portfolio and creating a competitive advantage. Technical indicators also support an upward trend: the price is above the SMA20 and SMA50, the MACD is crossing above its signal line, and the RSI is around 68, near overbought territory but not yet excessive. A slight increase in the stock price can be expected within 1-3 days, though market competition and regulatory risks should be considered.